$CLOV

Clover Health Investments (CLOV) reported Q2 adjusted EBITDA of $41 million and GAAP net income of $28 million. For the first half of 2026, it posted $81 million adjusted EBITDA and $55 million GAAP net income, with $443 million cash and investments and no debt. The company raised 2026 guidance to $2.92B-$3.0B revenue and $70M-$85M adjusted EBITDA, and discussed cohort maturation and 4.5-star ratings for 2027.

Clover Health (CLOV) shares rose about 12.7% to $4.67 after the company reported Q2 results showing profitability. Clover posted net income of $28.0 million on revenue of $743.2 million, its second straight profitable quarter, and raised 2026 guidance for revenue and adjusted EBITDA. The article also cites DOJ/SEC inquiries and CMS star-rating appeal.

A financial results roundup covers multiple insurers and MGAs. MetLife reported Q2 net income of $705m and adjusted EPS $2.43. Prudential posted Q2 net income of $985m and record individual life sales. Corebridge reported a $16m net loss and merger approval. Palomar, Heritage, TWFG, Root, Trupanion and Clover Health also reported Q2 figures and guidance updates.

Clover Health (NASDAQ: CLOV) reported Q2 CY2026 revenue of $743.2 million, up 55.6% year over year, topping Wall Street estimates by about 2%. Full-year revenue guidance was $2.96 billion at the midpoint, about 1.7% above consensus. GAAP EPS was $0.05, $0.02 above estimates. Shares rose 10.3% to $4.58.

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q26exx991xearningsrelease.htm EX-99.1 Document Exhibit 99.1 Clover Health Reports Second Quarter 2026 Results Business Highlights: • Delivered strong second quarter 2026 GAAP Net Income alongside continued market-leading Medicare Advantage membership growth • Improved

Clover Health (NASDAQ: CLOV) will report earnings Wednesday after market close. The company last quarter reported revenue of $749.2 million, up 62% year on year, and added 41,970 customers to 155,773. Analysts expect this quarter’s revenue to rise 52.5% y/y. The article cites an average analyst price target of $4.58 versus a $4.35 share price.

Clover Health Investments CEO Andrew Toy sold 62,711 shares of Class A stock on July 15, 2026 for about $292,860 to cover tax withholding tied to RSU vesting, according to an SEC Form 4. He retained about 9.5 million shares (~2% ownership). The article also cites CLOV’s recent court order and a July data breach, with earnings due early August.

Clover Pakistan Limited said in a PSX filing it has signed an exclusive distributorship and stockist agreement with UK-based CITA-UK to market and distribute CITA-UK EV chargers, accessories, and related equipment in Pakistan. The company said the deal supports its strategy to expand into EV infrastructure and green energy.

Clover Health (CLOV) shares rose about 7% to $2.39 after UnitedHealth Group (UNH) reported strong Q1 2026 results and raised its full-year adjusted net earnings outlook to over $18.25 per share, lifting sentiment for health insurers. Clover also cited 53% YoY Medicare Advantage membership growth and reiterated 2026 GAAP net income profitability guidance. Analysts maintain a Hold rating and a $2.90 average target.

Clover Health Investments said in a regulatory filing it detected unusual logins on July 4 and later found a hacker accessed three employee accounts via social engineering. The accounts could view some personal and protected health information, but not financial or claims systems. Clover is investigating with external experts, notified law enforcement, and says it expects no material business impact.